All In Biotech

Drug Trial Radar · NCT00502307

A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma

A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of Tivozanib (AV-951) in Patients With Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

272

Actual

Start

Oct 2007

Primary completion

Aug 2010

Study completion Aug 2010

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 17, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • Tivozanib (AV-951)Drug

    solid oral dosage form taken daily for three weeks per one month cycle

  • Placebo comparatorDrug

    solid oral capsule containing excipients dosed daily for three weeks per month

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs)Time frame: 28 weeks after study entry
  2. Objective Response [Complete Response (CR) + Partial Response (PR)] Rate at 16 Week Open-Label Period (All Treated Population)Time frame: 16 weeks after study entry
  3. Percentage of Randomly Assigned Subjects Remaining Progression Free at 12 Weeks Following Random Assignment to Tivozanib (AV-951) or PlaceboTime frame: 28 weeks after study entry

Locations

26 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Kolkata, India

  • Site not named

    Mumbai, India

  • Site not named

    New Delhi, India

  • Site not named

    Pune, India

  • Site not named

    Vellore, Tamil Nadu, India

  • Site not named

    Astrakhan, Russia

  • Site not named

    Kazan', Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Moscow, Russia

  • Site not named

    Obninsk, Russia

  • Site not named

    Pyatigorsk, Russia

  • Site not named

    Rostove-on-Don, Russia

  • Site not named

    Saint Petersburg, Russia

  • Site not named

    Sochi, Russia

  • Site not named

    Tomsk, Russia

  • Site not named

    Ufa, Russia

  • Site not named

    Velikiy Novgorod, Russia

  • Site not named

    Yoshkar-Ola, Russia

  • Site not named

    Cherkassy, Ukraine

  • Site not named

    Dnipro, Ukraine

  • Site not named

    Donetsk, Ukraine

  • Site not named

    Kharkiv, Ukraine

  • Site not named

    Lviv, Ukraine

  • Site not named

    Uzhhorod, Ukraine

  • Site not named

    Zaporizzhya, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.